istradefylline

Trade name: Nourianz

Small moleculeapproved

Approved

Aug 27, 2019

Istradefylline is a first-in-class adenosine A2A receptor antagonist antiparkinsonian agent and has been marketed as the brand name NOURIAST® in Japan since May 30, 2013. NOURIAST is indicated for the improvement of wearing-off phenomena in patients with Parkinson’s disease on concomitant treatment with levodopa-containing products. — NCATS

Clinical trial activity

26 trials · 9 clinical orgs · 1 marketing orgs

Phase 1
5
Phase 2
21
Phase 3
11
Phase 4
1

Earliest trial started Oct 1, 2000 (NCT00006337)

Timeline

2000s

  1. Jan 1, 2000

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2004

    Earliest Phase 3 Sponsor(trial)

2010s

  1. Jan 1, 2014

    Earliest Phase 1 Sponsor(trial)

  2. Aug 27, 2019

    Kyowa Kirin — Earliest FDA Approval

  3. Aug 27, 2019

    Kyowa Kirin — Marketing Organization

  4. Aug 27, 2019

    Kyowa Kirin — NDA Organization

Indications

Mechanism of action

Approval history

  • approvedAug 27, 2019

Chemistry & pharmacology

Loading structure…

SMILES

CCN1C2=C(N(C)C(\C=C\C3=CC(OC)=C(OC)C=C3)=N2)C(=O)N(CC)C1=O
Mol. weight
384.429 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

First in class

Sources

Also known as

  • 8-(2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-3,7-dihydro-7-methyl-1h-purine-2,6-dione
  • istradefylline
  • istradefylline
  • istradefylline
  • istradefylline
  • istradefylline
  • istradefylline
  • istradefylline
  • istradefylline
  • kw6002
  • kw 6002
  • kw-6002
  • kw-6002
  • kw-6002
  • kw-6002
  • kw-6002
  • nouriast

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05885360Phase 4Jan 20, 2023Georgetown University, Kyowa Hakko Kirin
NCT05217498Phase 1/Phase 2 (Phase 2)Sep 1, 2022Harvard University
NCT05333549Phase 2Jul 18, 2022Kyowa Hakko Kirin, Virginia Commonwealth University
NCT05377424Phase 1/Phase 2 (Phase 2)Jun 21, 2022ALS Association, University of Florida
NCT02609477Phase 1Jan 1, 2016Kyowa Hakko Kirin
NCT02610231Phase 3Dec 1, 2015Kyowa Hakko Kirin
NCT02256033Phase 1Aug 1, 2014Kyowa Hakko Kirin
NCT02174250Phase 1Jun 1, 2014Kyowa Hakko Kirin
NCT01968031Phase 3Oct 1, 2013Kyowa Hakko Kirin
NCT00957203Phase 3Oct 1, 2009Kyowa Hakko Kirin
NCT00955526Phase 3Jul 1, 2009Kyowa Hakko Kirin
NCT00455507Phase 2Mar 1, 2007Kyowa Hakko Kirin
NCT00250393Phase 2Nov 1, 2005Kyowa Hakko Kirin
NCT00199381Phase 3Oct 1, 2005Kyowa Hakko Kirin, Kyowa Kirin
NCT00199446Phase 2Jul 1, 2005Kyowa Hakko Kirin, Kyowa Kirin
NCT00199433Phase 2May 1, 2005Kyowa Hakko Kirin, Kyowa Kirin
NCT00199355Phase 2Apr 1, 2005Kyowa Hakko Kirin
NCT00203957Phase 3Mar 1, 2005University of Chicago
NCT00199394Phase 3Nov 1, 2004Kyowa Hakko Kirin
NCT00199368Phase 3Oct 1, 2004Kyowa Hakko Kirin, Kyowa Kirin
Showing 20 of 26 trials
Page 1 / 2

Organizations

Research & Development (9)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Kyowa Hakko KirinFor profit222042002
Kyowa KirinFor profit8022002
ALS AssociationAcademic/Hospital1012022
Georgetown UniversityAcademic/Hospital1112023
Harvard UniversityAcademic/Hospital1112022
National Institute of Neurological Disorders and Stroke (NINDS)Government1112000
University of ChicagoAcademic/Hospital1112005
University of FloridaAcademic/Hospital1112022
Virginia Commonwealth UniversityAcademic/Hospital1112022
9 organizations
Page 1 / 1

Marketing (2)

OrganizationOrg typeRelationshipDate
Kyowa KirinFor profitMKTGAug 27, 2019
Kyowa KirinFor profitNDAAug 27, 2019